Ugandan women with peripartum cardiomyopathy had high mortality

What the study found: The study found a 7.5% mortality rate in Ugandan women with peripartum cardiomyopathy, which the authors say aligns with global studies. It also reported a high thrombus burden, with thrombus in 10% and stroke in 2.5% of patients.
Why the authors say this matters: The authors suggest that the thrombus burden and stroke may indicate severe left ventricular (LV, the main pumping chamber of the heart) systolic dysfunction at presentation. They also suggest that frequent bromocriptine use alongside guideline-directed medical therapy (GDMT, standard treatment based on clinical guidelines) may explain the high rate of LV recovery.
What the researchers tested: The article examines clinical characteristics, echocardiographic findings, and 6-month outcomes in Ugandan women with peripartum cardiomyopathy. The abstract does not provide further details about the study design beyond these outcomes.
What worked and what didn't: Mortality was 7.5%, thrombus was observed in 10%, and stroke occurred in 2.5% of patients. Two-thirds of patients received bromocriptine in addition to GDMT, and the authors report a high rate of LV recovery in this cohort.
What to keep in mind: The abstract provides limited detail on methods, participant numbers, and how outcomes were measured. It also does not describe limitations beyond the findings reported here.

Key points

• Mortality in the cohort was 7.5%.
• Thrombus was reported in 10% of patients and stroke in 2.5%.
• The authors say these events may reflect severe left ventricular systolic dysfunction at presentation.
• Two-thirds of patients received bromocriptine in addition to guideline-directed medical therapy.
• The authors report a high rate of left ventricular recovery in this cohort.